Ghotme, K. A.,Barreto, G. E.,Echeverria, V.,Gonzalez, J.,Bustos, R. H.,Sanchez, M.,Leszek, J.,Yarla, N. S.,Gomez, R. M.,Tarasov, V. V.,Ashraf, G. M.,Aliev, G.

2017

Curr Top Med Chemcurr Top Med Chem

Gliomas: New Perspectives in Diagnosis, Treatment and Prognosis

Published

()

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use *Central Nervous System Neoplasms/diagnosis/genetics/therapy *Glioma/diagnosis/genetics/therapy Humans Signal Transduction/drug effects/genetics

17

1212

1438

1447

Gliomas are central nervous system tumors originated from glial cells, whose incidence and mortality is expected to rise in coming years, especially in developing countries. Diagnosis and classification of gliomas have largely relied on tumor histopathologic features that provide limited information regarding response to therapy or prognosis. Current treatment of gliomas is surgery combined with chemotherapy and/or radiotherapy. However, many tumors show a high resistance to these interventions, and recurrences are frequent since conventional therapies do not take into account the unique molecular features of different subtypes of glioma. Molecular genetics provide new insights in classifying gliomas and predicting response to therapy that can range from conventional treatments to new revolutionary therapeutic approaches. This article offers a review of the intracellular signaling pathways involved in carcinogenesis of gliomas, as well as a description of new tools for their diagnosis, prognosis, and treatment with a target-oriented approach.Gliomas are central nervous system tumors originated from glial cells, whose incidence and mortality is expected to rise in coming years, especially in developing countries. Diagnosis and classification of gliomas have largely relied on tumor histopathologic features that provide limited information regarding response to therapy or prognosis. Current treatment of gliomas is surgery combined with chemotherapy and/or radiotherapy. However, many tumors show a high resistance to these interventions, and recurrences are frequent since conventional therapies do not take into account the unique molecular features of different subtypes of glioma. Molecular genetics provide new insights in classifying gliomas and predicting response to therapy that can range from conventional treatments to new revolutionary therapeutic approaches. This article offers a review of the intracellular signaling pathways involved in carcinogenesis of gliomas, as well as a description of new tools for their diagnosis, prognosis, and treatment with a target-oriented approach.

1873-4294 (Electronic) 15

2017/01/05

http://www.ncbi.nlm.nih.gov/pubmed/28049399http://www.ncbi.nlm.nih.gov/pubmed/28049399

10.2174/1568026617666170103162639